Curalin supplement as add-on therapy for type 2 diabetes Mellitus
Authors' conclusion
Curalin treatment significantly reduced HbA1c over a period of 3 months and was well-tolerated.
Study context
- Population
- Patients aged 18–85 years with T2D and HbA1c 7.5–10 % under treatment with anti-diabetic drugs109 randomized
- Participants
- 135 patients
- Comparison
- Curalin supplement vs placebo, as add-on to anti-diabetic drugs
- Primary endpoint
- Change in HbA1c
- Follow-up
- 3 months
Methodological detailsplacebo-controlled, randomized 1:1
- Placebo-controlled
- Randomized 1:1
Primary result
As reported in the abstract
Mean reduction in HbA1c
Curalin
1.30
mean · SD 0.79 · %
Placebo
0.10
mean · SD 0.70 · %
P < 0.0001
Secondary outcomes
HbA1c decrease ≥ 0.5 % · 3 months
P < 0.0001
HbA1c reduction ≥ 1 % · 3 months
P < 0.0001
Treatment satisfaction (Diabetes Treatment Satisfaction Questionnaire (DTSQ))
- Curalin patients reported higher satisfaction (DTSQ)
- Exploratory endpoint
Safety
- No severe adverse events with Curalin
Original publication
Curalin supplement as add-on therapy for type 2 diabetes Mellitus. Diabetes Res Clin Pract. Published 6 November 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →